Payment overview · 2025
General Payments
$7,180.54
89 reported records · 10 companies
Healthcare provider profile · identity verified
Malik C. Spady, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Rheumatology · COVINGTON, LA · NPI 1649259789
Verified facts
What the public records show
CMS Open Payments records show Malik C. Spady, M.D. received $7,180.54 in general payments during 2025 across 89 reported records.
Mallinckrodt Hospital Products Inc. accounted for 78.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Acthar, Otezla, Rinvoq, Tremfya.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 177 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RINVOQ as an associated drug or biological on 279238 records involving 34343 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Rinvoq by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Vraylar by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Otezla by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Prolia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BENLYSTA as an associated drug or biological on 19884 records involving 5034 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Benlysta by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SIMPONI as an associated drug or biological on 23185 records involving 7011 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Simponi by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TREMFYA as an associated drug or biological on 292917 records involving 40097 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Tremfya by this doctor in 2024.
Mallinckrodt Hospital Products Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ACTHAR as an associated drug or biological on 35914 records involving 11592 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Acthar by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $5,615.21 | 78.2% | 13 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $502.50 | 7.0% | 33 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $286.81 | 4.0% | 13 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $229.90 | 3.2% | 8 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $206.02 | 2.9% | 10 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $125.00 | 1.7% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $94.39 | 1.3% | 5 | 2025 |
| Aurinia Pharma U.S., Inc. | Unresolved — no canonical attribution shown | $85.04 | 1.2% | 4 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $18.17 | 0.2% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $17.50 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $5,280.00 | 2 |
| Food and Beverage | $1,900.54 | 87 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $5,615.21 | 13 | 2025 |
Source payment records
|
|||||
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $362.30 | 24 | 2025 |
Source payment records
|
|||||
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $286.81 | 13 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $229.90 | 8 | 2025 |
Source payment records
|
|||||
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $140.20 | 9 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $118.38 | 6 | 2025 |
Source payment records
|
|||||
| ORENCIA Normalized: orencia |
Biological | E.R. Squibb & Sons, L.L.C. | $94.39 | 5 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $87.64 | 4 | 2025 |
Source payment records
|
|||||
| LUPKYNIS Normalized: lupkynis |
Drug | Aurinia Pharma U.S., Inc. | $85.04 | 4 | 2025 |
Source payment records
|
|||||
| Gazyva Normalized: gazyva |
Biological | Genentech USA, Inc. | $18.17 | 1 | 2025 |
Source payment records
|
|||||
| COSENTYX Normalized: cosentyx |
Drug | Novartis Pharmaceuticals Corporation | $17.50 | 1 | 2025 |
Source payment records
|
|||||
| ENBREL Normalized: enbrel |
Biological | Amgen Inc. | $9.59 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ACTHAR acthar |
2025 | Acthar | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 85 | exact normalized | Medicare Part D |
| RINVOQ rinvoq |
2025 | Rinvoq | 2024 | 113 | exact normalized | Medicare Part D |
| TREMFYA tremfya |
2025 | Tremfya | 2024 | 20 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
177 | 45 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | RINVOQ open payments reported associated product |
CMS Open Payments — General Payments 279238 supporting records · 34343 recipient NPIs · example record 1201352600 |
Rinvoq · 2024 Exact normalized brand match · 1 Part D row |
113 | 21 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
83 | 16 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
85 | 15 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
35 | 23 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | BENLYSTA open payments reported associated product |
CMS Open Payments — General Payments 19884 supporting records · 5034 recipient NPIs · example record 1190332353 |
Benlysta · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | SIMPONI open payments reported associated product |
CMS Open Payments — General Payments 23185 supporting records · 7011 recipient NPIs · example record 1174257377 |
Simponi · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | TREMFYA open payments reported associated product |
CMS Open Payments — General Payments 292917 supporting records · 40097 recipient NPIs · example record 1174257364 |
Tremfya · 2024 Exact normalized brand match · 1 Part D row |
20 | 11 |
| Mallinckrodt Hospital Products Inc. Exact reporting entity; no affiliate inference |
2025 | ACTHAR open payments reported associated product |
CMS Open Payments — General Payments 35914 supporting records · 11592 recipient NPIs · example record 1211945432 |
Acthar · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 1733 | 242 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 1143 | 131 |
| Prednisone | Prednisone | 885 | 285 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 881 | 248 |
| Tramadol Hcl | Tramadol Hcl | 719 | 153 |
| Mounjaro | Tirzepatide | 552 | 99 |
| Gabapentin | Gabapentin | 458 | 131 |
| Pregabalin | Pregabalin | 450 | 103 |
| Zolpidem Tartrate | Zolpidem Tartrate | 358 | 54 |
| Ozempic | Semaglutide | 333 | 60 |
| Fluconazole | Fluconazole | 310 | 152 |
| Alprazolam | Alprazolam | 219 | 47 |
| Tizanidine Hcl | Tizanidine Hcl | 200 | 63 |
| Levothyroxine Sodium | Levothyroxine Sodium | 194 | 63 |
| Eszopiclone | Eszopiclone | 182 | 41 |
| Pantoprazole Sodium | Pantoprazole Sodium | 178 | 59 |
| Linzess | Linaclotide | 177 | 45 |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 165 | 65 |
| Ondansetron Odt | Ondansetron | 154 | 57 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 150 | 33 |
| Potassium Chloride | Potassium Chloride | 149 | 48 |
| Duloxetine Hcl | Duloxetine Hcl | 148 | 42 |
| Clobetasol Propionate | Clobetasol Propionate | 144 | 55 |
| Meloxicam | Meloxicam | 139 | 46 |
| Celecoxib | Celecoxib | 134 | 43 |
| Leucovorin Calcium | Leucovorin Calcium | 133 | 52 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 132 | 32 |
| Amlodipine Besylate | Amlodipine Besylate | 123 | 34 |
| Methocarbamol | Methocarbamol | 122 | 45 |
| Montelukast Sodium | Montelukast Sodium | 119 | 41 |
| Mirtazapine | Mirtazapine | 118 | 28 |
| Cosentyx Sensoready (2 Pens) | Secukinumab | 117 | 20 |
| Ibuprofen | Ibuprofen | 117 | 29 |
| Methylprednisolone | Methylprednisolone | 115 | 73 |
| Promethazine Hcl | Promethazine Hcl | 114 | 32 |
| Rinvoq | Upadacitinib | 113 | 21 |
| Famotidine | Famotidine | 110 | 38 |
| Azithromycin | Azithromycin | 109 | 82 |
| Methotrexate | Methotrexate Sodium | 109 | 32 |
| Valacyclovir | Valacyclovir Hcl | 108 | 57 |
| Diclofenac Sodium | Diclofenac Sodium | 105 | 27 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 101 | 29 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 100 | 32 |
| Belsomra | Suvorexant | 93 | 27 |
| Baclofen | Baclofen | 88 | 19 |
| Buspirone Hcl | Buspirone Hcl | 85 | 25 |
| Otezla | Apremilast | 85 | 15 |
| Synthroid | Levothyroxine Sodium | 83 | 16 |
| Temazepam | Temazepam | 83 | 16 |
| Mupirocin | Mupirocin | 82 | 47 |
| Nystatin | Nystatin | 79 | 48 |
| Sulfasalazine Dr | Sulfasalazine | 78 | 28 |
| Meclizine Hcl | Meclizine Hcl | 76 | 26 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 74 | 19 |
| Trazodone Hcl | Trazodone Hcl | 73 | 22 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 67 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 66 | 17 |
| Armodafinil | Armodafinil | 66 | suppressed |
| Minoxidil | Minoxidil | 65 | 20 |
| Modafinil | Modafinil | 65 | 14 |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 64 | 14 |
| Skyrizi Pen | Risankizumab-Rzaa | 63 | 24 |
| Topiramate | Topiramate | 62 | 12 |
| Humira(Cf) Pen | Adalimumab | 61 | 11 |
| Lidocaine | Lidocaine | 60 | 22 |
| Enbrel Sureclick | Etanercept | 59 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 58 | 18 |
| Allopurinol | Allopurinol | 57 | 20 |
| Spironolactone | Spironolactone | 57 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 57 | 35 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 56 | 11 |
| Liothyronine Sodium | Liothyronine Sodium | 56 | 24 |
| Lorazepam | Lorazepam | 56 | 15 |
| Cevimeline Hcl | Cevimeline Hcl | 54 | 15 |
| Clonazepam | Clonazepam | 54 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 54 | 24 |
| Bupropion Xl | Bupropion Hcl | 53 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 52 | 14 |
| Colchicine | Colchicine | 51 | 22 |
| Dexamethasone | Dexamethasone | 50 | 34 |
| Diazepam | Diazepam | 50 | 12 |
| Memantine Hcl | Memantine Hcl | 49 | 17 |
| Sodium Chloride | 0.9 % Sodium Chloride | 49 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 49 | 15 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 48 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 47 | 33 |
| Losartan Potassium | Losartan Potassium | 47 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 46 | 15 |
| Armour Thyroid | Thyroid,pork | 45 | suppressed |
| Taltz Autoinjector | Ixekizumab | 44 | suppressed |
| Orencia Clickject | Abatacept | 42 | suppressed |
| Cilostazol | Cilostazol | 41 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 41 | suppressed |
| Benlysta | Belimumab | 40 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 40 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 40 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 37 | 21 |
| Sucralfate | Sucralfate | 37 | 13 |
| Tretinoin | Tretinoin | 37 | 16 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 36 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 36 | suppressed |
| Finasteride | Finasteride | 35 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 35 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 35 | 26 |
| Prolia | Denosumab | 35 | 23 |
| Sildenafil Citrate | Sildenafil Citrate | 35 | suppressed |
| Furosemide | Furosemide | 33 | suppressed |
| Nabumetone | Nabumetone | 33 | suppressed |
| Zaleplon | Zaleplon | 33 | suppressed |
| Omeprazole | Omeprazole | 32 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 31 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 31 | 12 |
| Simponi | Golimumab | 31 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 30 | suppressed |
| Cosentyx Unoready Pen | Secukinumab | 30 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 30 | suppressed |
| Azathioprine | Azathioprine | 29 | 13 |
| Trintellix | Vortioxetine Hydrobromide | 29 | suppressed |
| Acyclovir | Acyclovir | 28 | suppressed |
| Leflunomide | Leflunomide | 28 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 27 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 27 | 12 |
| Atorvastatin Calcium | Atorvastatin Calcium | 26 | suppressed |
| Cosentyx Sensoready Pen | Secukinumab | 26 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 26 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 26 | suppressed |
| Progesterone | Progesterone, Micronized | 26 | suppressed |
| Ketoconazole | Ketoconazole | 25 | suppressed |
| Lisinopril | Lisinopril | 25 | 11 |
| Metoclopramide Hcl | Metoclopramide Hcl | 25 | 13 |
| Enbrel Mini | Etanercept | 24 | suppressed |
| Fentanyl | Fentanyl | 24 | suppressed |
| Kevzara | Sarilumab | 24 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 24 | suppressed |
| Actemra Actpen | Tocilizumab | 23 | suppressed |
| Aripiprazole | Aripiprazole | 23 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 23 | 15 |
| Megestrol Acetate | Megestrol Acetate | 23 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 23 | suppressed |
| Acthar | Corticotropin | 22 | suppressed |
| Febuxostat | Febuxostat | 22 | suppressed |
| Hydrocortisone | Hydrocortisone | 22 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 21 | suppressed |
| Ibuprofen-Famotidine | Ibuprofen/Famotidine | 21 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 21 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 20 | suppressed |
| Tremfya | Guselkumab | 20 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Gammagard Liquid | Immun Glob G(Igg)/Gly/Iga Ov50 | 18 | suppressed |
| Metformin Hcl | Metformin Hcl | 18 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Piroxicam | Piroxicam | 18 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Np Thyroid | Thyroid,pork | 17 | suppressed |
| Olumiant | Baricitinib | 17 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 17 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 16 | suppressed |
| Chlorzoxazone | Chlorzoxazone | 16 | suppressed |
| Creon | Lipase/Protease/Amylase | 16 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 15 | suppressed |
| Atenolol | Atenolol | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Carvedilol | Carvedilol | 15 | suppressed |
| Dapsone | Dapsone | 15 | suppressed |
| Diphenhydramine Hcl | Diphenhydramine Hcl | 15 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 15 | suppressed |
| Indomethacin | Indomethacin | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 15 | suppressed |
| Privigen | Immun Glob G(Igg)/Pro/Iga 0-50 | 15 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 14 | suppressed |
| Diclofenac Sodium-Misoprostol | Diclofenac Sodium/Misoprostol | 14 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Lubiprostone | Lubiprostone | 14 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 14 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Fluocinonide | Fluocinonide | 13 | suppressed |
| Litfulo | Ritlecitinib Tosylate | 13 | suppressed |
| Butalbital-Acetaminophen | Butalbital/Acetaminophen | 12 | suppressed |
| Cimzia (2 Pack) | Certolizumab Pegol | 12 | suppressed |
| Humira Pen | Adalimumab | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Forteo | Teriparatide | 11 | suppressed |
| Klor-Con | Potassium Chloride | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
| Trulance | Plecanatide | 11 | suppressed |
| Vraylar | Cariprazine Hcl | 11 | suppressed |
| Xiidra | Lifitegrast | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $7,180.54 · 89 records | Mallinckrodt Hospital Products Inc. | ACTHAR, Bimzelx, COSENTYX, ENBREL, Gazyva, LUPKYNIS, ORENCIA, OTEZLA, RINVOQ, SKYRIZI, TAVNEOS, TREMFYA | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Acthar play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error